Page 78 - Read Online

Yonemura et al. J Cancer Metastasis Treat 2022;8:43 https://dx.doi.org/10.20517/2394-4722.2022.49 Page 11 of 12

DECLARATIONS
Authors’ contributions
Writing: Yonemura Y
Conceptualization: Ishibashi H, Mizumoto A, Fujita T
Format anlaysis: Liu Y, Wakama S
Data analysis: Sako S, Takao N, Kitai T, Katayama K, Kamada Y Taniguchi K, Fujimoto D
All authors have read and agreed to the published version of the manuscript.

Availability of data and materials
No applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there is no conflict of interest.

Ethical approval and consent to participate
The study was approved by the ethical committee of Kishiwada Tokushukai hospital, the protocol; code of
19-35, that title is “A study of comprehensive treatment for peritoneal metastasis”. It was approved on 15
Onctober 2007.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. Mery E, Hommel-Fontaine J, Capovilia M, et al. Peritoneal malignant mesothelioma: review and recent data. Ann Pathol 2014;34:26-
33. DOI PubMed
2. Consonni D, Calvi C, De Matteis S, et al. Peritoneal mesothelioma and asbestos exposure: a population-based case-control study in
Lombardy, Italy. Occup Environ Med 2019;76:545-53. DOI PubMed PMC
3. Kanarek MS, Liegel JCO. Asbestos intalc and mesothelioma: review of the causality using epidemiology. ESMED 2020:8. DOI
4. Bridda A, Padoan I, Mencarelli R, et al. Peritoneal mesothelioma: a review. MedGenMed 2007;9:32. PubMed PMC
5. Carbone M, Adsumolli PA, Alexander HR, et al. Mesothelioma: scientific clues for prevention, diagnosia and therapy. CA Cancer J
Clin 2019;69:402-29. DOI
6. Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health
Organization between 1994 and 2008. Bull World Health Organ 2011;89:716-24. DOI PubMed PMC
7. Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol 2007;18:985-90. DOI PubMed
8. Oddone E, Bollon J, Nava CR, et al. Forecast of malignant peritoneal mesothelioma mortality in Italy up to 2040. Int J Environ Res
Public Health 2020;18:160. DOI PubMed PMC
9. Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005.
Cancer Causes Control 2009;20:935-44. DOI PubMed
10. Kusamura S, Kepenekian V, Villeneuve L, et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for
diagnosis, treatment and follow-up. Eur J Surg Oncol 2021;47:36-59. DOI PubMed
11. Verwaal VJ, Kusamura S, Baratti D, Deraco M. The eligibility for local-regional treatment of peritoneal surface malignancy. J Surg
Oncol 2008;98:220-3. DOI PubMed
12. Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in
improved survival. Eur J Surg Oncol 2017;43:1228-35. DOI PubMed
13. Cartenni G, Manegold C, Martin Garcia G, et al. Malignant peritoneal mesothelioma-results from the international expanded access
program using pemetrexed alone or in combination with a platinum agent. Lung Cancer 2009;64:211-18. DOI